News & Events

Vivli Board names Rebecca Li CEO

Vivli announced that its Board of Directors has promoted Rebecca Li to the position of CEO. Li previously held the position of Executive Director and has been with the Vivli since its founding when it launched as a project from the MRCT Center of the Brigham and Women’s Hospital and Harvard.

“Rebecca has overseen the extraordinary growth of Vivli from the start and we are excited that she will continue to lead Vivli through the next phase of growth as we aim to go even further in our mission to make clinical trial available for research. She has demonstrated herself to be an exceptional team leader and strategic thinker with a clear vision for how we will develop globally in the coming years,” said Dr. Michael Stebbins, Vivli’s Board Chair.

“I am privileged to lead Vivli and envision further expanding our successful platform technology into Europe and Asia as we enter our next phase of innovation and growth” said Dr. Rebecca Li.

Vivli was founded in 2018 as a non-profit organization that is currently the largest individual participant-level (IPD) data sharing platform focused on sharing clinical trial data serving the international research community.


Azusa Tsukida

Azusa joined the Vivli team in 2022 as a Senior Advisor. Azusa will be focusing on clinical data sharing and outreach in Japan. Before joining Vivli, she has nearly 15 years’ experience as leader for the Biostatistics & Programming Department at Sanofi in Tokyo. She holds a degree in algebraic geometry from Tokyo Woman’s Christian University.

Independent Review Panel

An experienced independent consultant acts as the secretariat for the Independent Review Panel (IRP). Data contributors can choose to have an independent, neutral party oversee the review of requests by accessing the esteemed Independent Review Panel who will review research proposals based on their merit.

For more information, please review the Independent Review Panel Charter. Read more about the IRP members.



Vivli Committees

The Vivli Steering Committee comprises representatives from Vivli members. This group includes institutional data contributors from academia, governmental, industry, and non-profit organizations and meets regularly to discuss operational, governance, and policy issues.

The Vivli External Advisory Committee brings together a diverse group of influential leaders with a commitment to data transparency. These leaders provide knowledge and insights based on their experience and expertise in their respective fields on a broad range of issues related to governance, implementation, and strategic planning. This external perspective supports Vivli’s growth as an institution.

  • Sergio Bonini, Italian National Research Council (CNR), Institute of Translational Pharmacology
  • Jeffrey Drazen,  New England Journal of Medicine 
  • Dave Evans, CDISC
  • Nina Hill, Hill Scientific and Public Affairs
  • Karmela Krleza-Jeric, Impact Observatory, MedILS  
  • Young-Joo Lee, Johns Hopkins University
  • Bernard Lo, UCSF
  • Joshua Mann, VHL Alliance
  • Jan McGonagle, Amoskeag Health
  • Vasee Moorthy, World Health Organization 
  • Brian Nosek, Center for Open Science 
  • Amy Nurnberger, MIT
  • Jane Perlmutter, Gemini Group 
  • Larysa Rydzewska, MRC Clinical Trials Unit at UCL
  • Lon Schneider, University of Southern California
  • Carolyn Shore, National Academies of Sciences (NAS) Observer
  • Karla Soares-Weiser, Cochrane
  • Catrin Tudur Smith, Liverpool University
  • Megan von Isenburg, Duke Medical Center Library and Archives
  • David Vulcano,  HCA Healthcare
  • Daoxin Yin, Peking University, Health Science Center


Marcia Levenstein

Marcia recently retired as a VP of Statistics at Pfizer with responsibility for clinical development in the CVMET therapeutic area and globally sponsored Pfizer’s China Research & Development Center (CRDC) Statistics organization.  While at Pfizer Marcia led the global biometrics organization for Pfizer’s marketed medicines clinical research programs and established regional biometrics centers for Latin America, Europe, Asia and China. Marcia has extensive experience in the analysis and interpretation of clinical trial data across numerous therapeutic areas, particularly in Cardiovascular and Anti-infectives.  She has served as the statistical leader for regulatory submissions with the responsibility of ensuring biometrics business support of the global pharmaceutical product portfolio. In addition to her role leading Statistics groups, Marcia was a member of Pfizer’s team for the clinical trial disclosure policy, and played a key leadership role in defining Pfizer policy on the issue.  She was a member of Pfizer’s internal steering committee for their Bioethics Advisory Panel and a member of Pfizer’s Clinical Trials Policy Group. She is a member of the Stevens Institute Business Intelligence & Analytics Program Advisory Board, which she joined in 2012. She is a member of the ASA Committee on Professional Ethics. Marcia holds BS degrees in Mathematics and Life Sciences from MIT, an MS in Biostatistics form UNC,  and an ScD in Biostatistics from Harvard University. She received a Masters in Bioethics form U Penn in 2012.

Partners and Funders


Vivli and Cochrane work together to use the Cochrane ontology to power the Vivli search. Clinical trials included or cited on the Vivli platform are annotated using the Cochrane PICO ontology and vocabulary, supporting discoverability of data and making it easier for researchers to access clinical trial data. Cochrane’s mission is to promote evidence-informed health decision-making by producing high-quality, relevant, accessible systematic reviews and other synthesized research evidence.

Cochrane PICO Vocabulary – Copyright ©2018 Cochrane. All rights reserved.
Cochrane PICO Ontology – Creative Commons Attribution – NonCommercial-NoDerivatives 4.0 International License


Instem is partnered with Vivli to lower the barriers trialists face when it comes to sharing clinical research data responsibly. Instem offers expert-led outsourced data anonymization services powered by industry-leading anonymization software, Blur™. We are committed to helping your organization protect patient data while expediting medical innovation. Learn more about Blur, or request a call with our experts if you’re ready to start an anonymization project.





Vivli partners with DataCite to mint persistent digital identifiers (DOI’s) for studies shared on Vivli as well as for publications resulting from data sharing on Vivli. DataCite is a leading global non-profit organization that provides persistent identifiers (DOIs) for research data. DataCite’s goal is to help the research community locate, identify, and cite research data with confidence.

As a member of DataCite, Vivli is included in the Re3 Data Repository.





Microsoft is a key partner in the Vivli platform. The Vivli platform is built entirely on the Microsoft Azure cloud server, which provides unparalleled data security coupled with a truly global presence. Microsoft in Health is committed to empowering health systems of tomorrow with better analytics, improved collaboration, and safer devices for real impact and better health today.




Real Life Sciences (RLS) specializes in anonymizing clinical data on behalf of commercial study sponsors, academic research teams and data contributors. Using its purpose-built RLS Protect anonymization platform, RLS is a trusted advisor and partner to deliver anonymized data for sharing on the Vivli platform. RLS will engage with your team to lead the end-to-end process of anonymizing your data for sharing while mitigating the risk of subject reidentification and preserving clinical utility. RLS is a partner of the Bill & Melinda Gates Foundation. For more information on services offered by Real Life Sciences for Vivli contributors, please email


Vivli collaborates with Privacy Analytics, an industry leader in health data-sharing methods and technologies, data security and de-identification. This partnership offers anonymization services to individuals and organizations who wish to share clinical data on the Vivli platform. By collaborating with Privacy Analytics, Vivli is driving forward the use of emerging technologies to promote and enable clinical data sharing, with the goal of developing new discoveries to improve human health. For more information on services offered by Privacy Analytics to Vivli data contributors, please email


Vivli’s outside counsel for corporate, regulatory and intellectual property matters is Ropes & Gray LLP, a preeminent global law firm with broad expertise in digital health and research. Ropes & Gray provides Vivli legal services on a pro bono basis, illustrating the firm’s longstanding public service commitment.





TrialScope and Vivli work together to provide an end-to-end solution for disclosure and data sharing. TrialScope is the global leader in clinical trial disclosure and transparency management technology, supporting 13 of the top 15 industry clinical trial sponsors worldwide. TrialScope provides proven solutions that optimize the efficiency of disclosure activities, maximize trial data transparency, and foster more informed, engaged patients through open research sharing. To learn more about TrialScope, visit  



Vivli is grateful for the financial support and partnership of the following organizations in helping us deliver our mission to promote, coordinate, and facilitate clinical research data sharing through the creation and implementation of a sustainable global data-sharing and analytics platform:













If you are interested in supporting Vivli, please email

Frank Rockhold

Frank has had diverse research interests and consulting experience in industry and academia including clinical trials design, data monitoring, data standards, benefit/risk, real world evidence, cardiovascular research, and, most recently, safety and pharmacovigilance.  He has been a leader in the scientific community in promoting data disclosure and transparency in clinical research.  Frank is a full-time Professor of Biostatistics and Bioinformatics at Duke Clinical Research Institute.  He is also a Managing Partner of HunterRockhold, Inc., which provides strategic consulting to Industry, Government, and Academia in the areas of clinical trials, pharmacovigilance, data disclosure, and transparency.  Frank’s 40-year career includes senior research positions at Lilly, Merck, and GlaxoSmithKline, where he recently retired as Senior Vice President of Global Clinical Safety and Pharmacovigilance.  He has held faculty appointments at six different universities. Frank served for 9 years on the board of directors of the non-profit CDISC, most recently as Chairman, and is past president of the Society for Clinical Trials. He is a member of the PCORI Clinical Trials Advisory Panel and is on the board of the Frontier Science and Technology Research Foundation.  Frank is widely published in major scientific journals across a wide variety of research topics. He holds a BA in Statistics from The University of Connecticut, an ScM in Biostatistics from the Johns Hopkins University, and a PhD in Biostatistics from the Medical College of Virginia. Frank is a Fellow of both the American Statistical Association and the Society for Clinical Trials and an Accredited Professional Statistician, PStat®.